The renin-angiotensin system in the pathophysiology of type 2 diabetes

Obesity Facts

Volumn 5, Issue 4, 2012, Pages 611-624

  Goossens, Gijs H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adipose tissue; Insulin resistance; Insulin secretion; Renin angiotensin system; Skeletal muscle

Indexed keywords

CANDESARTAN; CAPTOPRIL; GLUCOSE TRANSPORTER 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAMIPRIL; REACTIVE OXYGEN METABOLITE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ADIPOCYTE; ADIPOSE TISSUE; ADIPOSE TISSUE BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CYSTIC FIBROSIS; ESSENTIAL HYPERTENSION; GLUCOSE METABOLISM; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RELEASE; INSULIN SENSITIVITY; MICRODIALYSIS; MUSCLE BLOOD FLOW; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS BLOOD FLOW; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE METABOLISM;

ADIPOSE TISSUE; DIABETES MELLITUS, TYPE 2; FIBROSIS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MUSCLE, SKELETAL; OBESITY; OXIDATIVE STRESS; PANCREAS; REGIONAL BLOOD FLOW; RENIN-ANGIOTENSIN SYSTEM;

EID: 84866423935     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000342776     Document Type: Review

References (134)

1. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Porte D Jr: Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991; 40: 166-180.
3. Goossens GH, Blaak EE, van Baak MA: Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003; 4: 43-55.
4. Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-1277.
5. Ferrario CM, Strawn WB: Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128.
6. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
7. Unger T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A; discussion 10A.
8. Henriksen EJ: Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 293:R974-980.
9. Leung PS: Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in type 2 diabetes. Diabet Med 2007; 24: 110-116.
10. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR: Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128-139.
11. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI: The Impact of ACE inhibitors or angiotensin II Type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-2266.
12. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
13. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
14. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
15. Kahn CR: Medicine. Can we nip obesity in its vascular bud? Science 2008; 322: 542-543.
16. Tikellis C, Cooper ME, Thomas MC: Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int J Biochem Cell Biol 2006; 38: 737-751.
17. Carlsson PO: The renin-angiotensin system in the endocrine pancreas. JOP 2001; 2: 26-32.
18. Huang Z, Jansson L, Sjoholm A: Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate. Biochem Biophys Res Commun 2006; 346: 26-32.
19. Kampf C, Lau T, Olsson R, Leung PS, Carlsson PO: Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts. Diabetologia 2005; 48: 1159-1167.
20. Peach MJ: Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977; 57: 313-370.
21. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
22. Yuan L, Li X, Li J, Li HL, Cheng SS: Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 2010; DOI: 10.1007/s00592-010-0210-8.
23. Chu KY, Lau T, Carlsson PO, Leung PS: Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006; 55: 367-374.
24. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R, Watada H: Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006; 344: 1224-1233.
25. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS: Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010; 55: 715-721.
26. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME: Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-997.
27. Lau T, Carlsson PO, Leung PS: Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-248.
28. Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH, Son HS, Cha BY, Lee KW, Son HY, Kang SK, Park CG, Lee IK, Yoon KH: Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 2004; 316: 114-122.
29. Lupi R, Del Guerra S, Bugliani M, Boggi U, Mosca F, Torri S, Del Prato S, Marchetti P: The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 2006; 154: 355-361.
30. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
31. Suzuki K, Nakagawa O, Aizawa Y: Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens 2008; 30: 309-314.
32. Bokhari S, Israelian Z, Schmidt J, Brinton E, Meyer C: Effects of angiotensin II type 1 receptor blockade on beta-cell function in humans. Diabetes Care 2007; 30: 181.
33. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC: Effect of Rosiglitazone and Ramipril on -cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010; 33: 608-613.
34. van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M: Valsartan Improves -cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 2011; 34: 845-851.
35. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin- dependent diabetes mellitus. Eur J Clin Invest 1987; 17: 448-454.
36. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P: A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12: 298-303.
37. Morel Y, Gadient A, Keller U, Vadas L, Golay A: Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995; 26: 306-311.
38. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M: ACE inhibition improves insulinsensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6: 175-179.
39. Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T: The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens 1995; 8: 276-281.
40. Shieh SM, Sheu WH, Shen DD, Fuh MM, Jeng CY, Jeng JR, Chen YD, Reaven GM: Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment. Am J Hypertens 1992; 5: 506-510.
41. Suzuki M, Ikebuchi M, Yokota C, Shinozaki K, Harano Y: Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens 1995; 17: 1257-1268.
42. Torlone E, Rambotti AM, Perriello G, Botta G, Santeusanio F, Brunetti P, Bolli GB: ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991; 34: 119-125.
43. Vuorinen-Markkola H, Yki-Jarvinen H: Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995; 44: 85-89.
44. Heinemann L, Heise T, Ampudia J, Sawicki P, Sindelka G, Brunner G, Starke AA: Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest 1995; 25: 595-600.
45. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT: Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Horm Metab Res 1999; 31: 418-423.
46. Ludvik B, Kueenburg E, Brunnbauer M, Schernthaner G, Prager R: The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension. J Cardiovasc Pharmacol 1991; 18(suppl 2):S157-159.
47. New JP, Bilous RW, Walker M: Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days' treatment with trandolapril. Diabet Med 2000; 17: 134-140.
48. Petrie JR, Morris AD, Ueda S, Small M, Donnelly R, Connell JM, Elliott HL: Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 2000; 85: 1882-1889.
49. Pratt MC, Lewis-Barned NJ, Walker RJ: A comparison between enalapril and captopril on insulin sensitivity in normotensive healthy volunteers. Aust N Z J Med 1993; 23: 652-655.
50. Reaven GM, Clinkingbeard C, Jeppesen J, Maheux P, Pei D, Foote J, Hollenbeck CB, Chen YD: Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8: 461-466.
51. Santoro D, Natali A, Palombo C, Brandi LS, Piatti M, Ghione S, Ferrannini E: Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992; 20: 181-191.
52. Valensi P, Derobert E, Genthon R, Riou JP: Effect of ramipril on insulin sensitivity in obese patients. Timecourse study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp. Diabetes Metab 1996; 22: 197-200.
53. Wiggam MI, Hunter SJ, Atkinson AB, Ennis CN, Henry JS, Browne JN, Sheridan B, Bell PM: Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens 1998; 16: 1651-1657.
54. Goossens GH, Blaak EE, Schiffers PM, Saris WH, van Baak MA: Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects. Diabetologia 2006; 49: 3009-3016.
55. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP: The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-1007.
56. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z: The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009; 52: 752-764.
57. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ: Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 2006; 55: 1436-1442.
58. de Jongh RT, Serne EH, RG IJ, de Vries G, Stehouwer CD: Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004; 109: 2529-2535.
59. Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S: Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 2003; 284:E241-258.
60. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ: Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004; 53: 1418-1423.
61. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD, Clark MG: Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 2002; 51: 3492-3498.
62. Baron AD, Clark MG: Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 1997; 17: 487-499.
63. Goossens GH, Blaak EE, Saris WH, Van Baak MA: Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 2004; 89: 2690-2696.
64. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J: Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990; 13: 1109-1111.
65. Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, Liu Z: Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension 2010; 55: 523-530.
66. Rizzoni D, Pasini E, Flati V, Rodella LF, Paiardi S, Assanelli D, De Ciuceis C, Porteri E, Boari GE, Rezzani R, Speca S, Favero G, Martinotti S, Toniato E, Platto C, Agabiti-Rosei E: Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. J Hypertens 2008; 26: 1595-1601.
67. Sabino B, Lessa MA, Nascimento AR, Rodrigues CA, Henriques MG, Garzoni LR, Levy BI, Tibirica E: Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis. J Cardiovasc Pharmacol 2008; 51: 402-409.
68. Sloniger JA, Saengsirisuwan V, Diehl CJ, Dokken BB, Lailerd N, Lemieux AM, Kim JS, Henriksen EJ: Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat. Am J Physiol Endocrinol Metab 2005; 288:E1074-1081.
69. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ: ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999; 277:R332-336.
70. Miyata T, Taguchi T, Uehara M, Isami S, Kishikawa H, Kaneko K, Araki E, Shichiri M: Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol 1998; 138: 344-352.
71. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-879.
72. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS: Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008; 294:E345-351.
73. Marchionne EM, Diamond-Stanic MK, Prasonnarong M, Henriksen EJ: Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2012; 302:R137-142.
74. Lastra G, Habibi J, Whaley-Connell AT, Manrique C, Hayden MR, Rehmer J, Patel K, Ferrario C, Sowers JR: Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-2568.
75. Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, Hayden MR, Wei Y, Ferrario C, Sowers JR: Low-dose spironolactone reduces reactive oxygen species generation and improves insulinstimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008; 295:E110-116.
76. Iwai M, Kanno H, Tomono Y, Inaba S, Senba I, Furuno M, Mogi M, Horiuchi M: Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 2010; 28: 1471-1481.
77. Kang YS, Lee MH, Song HK, Hyun YY, Cha JJ, Ko GJ, Kim SH, Lee JE, Han JY, Cha DR: Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 2011; 26: 1194-1204.
78. Schrauwen P, Schrauwen-Hinderling V, Hoeks J, Hesselink MK: Mitochondrial dysfunction and lipotoxicity. Biochim Biophys Acta 2010; 1801: 266-271.
79. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW 3rd, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neufer PD: Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119: 573-581.
80. Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin MA, Morio B, Vidal H, Rieusset J: Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest 2008; 118: 789-800.
81. Lee HY, Choi CS, Birkenfeld AL, Alves TC, Jornayvaz FR, Jurczak MJ, Zhang D, Woo DK, Shadel GS, Ladiges W, Rabinovitch PS, Santos JH, Petersen KF, Samuel VT, Shulman GI: Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metab 2010; 12: 668-674.
82. Mitsuishi M, Miyashita K, Muraki A, Itoh H: Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes 2009; 58: 710-717.
83. Goossens GH: The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94: 206-218.
84. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM: Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17: 555-560.
85. Jones BH, Standridge MK, Taylor JW, Moustaid N: Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol 1997; 273:R236-242.
86. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM: Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998; 83: 3925-3929.
87. Schling P, Mallow H, Trindl A, Loffler G: Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord 1999; 23: 336-341.
88. Schling P, Schafer T: Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity. J Biol Chem 2002; 277: 48066-48075.
89. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG: Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res 1994; 35: 1378-1385.
90. Goossens GH, Jocken JW, Blaak EE, Schiffers PM, Saris WH, van Baak MA: Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of beta-adrenergic stimulation. Hypertension 2007; 49: 542-547.
91. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Cajlakovic M, Ribitsch V, Clement K, Blaak EE: Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 2011; 124: 67-76.
92. Eriksson JW, Smith U, Waagstein F, Wysocki M, Jansson PA: Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes 1999; 48: 1572-1578.
93. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E: A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38: 1213-1217.
94. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE: Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000; 43: 1498-1506.
95. Lundgren M, Svensson M, Lindmark S, Renstrom F, Ruge T, Eriksson JW: Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia 2007; 50: 625-633.
96. Frayn KN: Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001; 60: 375-380.
97. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-1707.
98. Saiki A, Koide N, Watanabe F, Murano T, Miyashita Y, Shirai K: Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system. Metabolism 2008; 57: 1093-1100.
99. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K: Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-1982.
100. Munoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE: Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 2009; 27: 2409-2420.
101. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M: Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21: 206-212.
102. Goossens GH, Moors CCM, van der Zijl NJ, Venteclef N, Alili R, Jocken JWE, Essers Y, Cleutjens JP, Clément K, Diamant K, Blaak EE: Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PLoS ONE 2012; 7:e39930.
103. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 2004; 43: 993-1002.
104. Schupp M, Janke J, Clasen R, Unger T, Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
105. Kintscher U, Foryst-Ludwig A, Unger T: Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets 2008; 12: 1257-1263.
106. Jones BH, Standridge MK, Moustaid N: Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138: 1512-1519.
107. Boschmann M, Ringel J, Klaus S, Sharma AM: Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 2001; 9: 486-491.
108. Boschmann M, Rosenbaum M, Leibel RL, Segal KR: Metabolic and hemodynamic responses to exercise in subcutaneous adipose tissue and skeletal muscle. Int J Sports Med 2002; 23: 537-543.
109. Goossens GH, Blaak EE, Arner P, Saris WH, van Baak MA: Angiotensin II: a hormone that affects lipid metabolism in adipose tissue. Int J Obes (Lond) 2007; 31: 382-384.
110. Boschmann M, Adams F, Klaus S, Sharma AM, Luft FC, Jordan J: Differential response to interstitial angiotensin II in normal weight and obese men. Int J Obes Relat Metab Disord 2003; 27(suppl):S52.
111. Boschmann M, Adams F, Schaller K, Franke G, Sharma AM, Klaus S, Luft FC, Jordan J: Hemodynamic and metabolic responses to interstitial angiotensin II in normal weight and obese men. J Hypertens 2006; 24: 1165-1171.
112. Boschmann M, Kreuzberg U, Engeli S, Adams F, Franke G, Klaua S, Scholze J, Weidinger G, Luft FC, Sharma AM, Jordan J: The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and betareceptor blockade in obese hypertensive subjects. Horm Metab Res 2006; 38: 323-329.
113. Lee MH, Song HK, Ko GJ, Kang YS, Han SY, Han KH, Kim HK, Han JY, Cha DR: Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008; 74: 890-900.
114. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T: Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724.
115. Pscherer S, Heemann U, Frank H: Effect of renin-angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care 2010; 33: 914-919.
116. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
117. Tian F, Luo R, Zhao Z, Wu Y, Ban D: Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2010; 118: 258-265.
118. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, Acikel C, Oguz Y, Yavuz I, Vural A: Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147-153.
119. Fliser D, Buchholz K, Haller H: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
120. Aksnes TA, Seljeflot I, Torjesen PA, Hoieggen A, Moan A, Kjeldsen SE: Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 2007; 56: 1470-1477.
121. Goossens GH, McQuaid SE, Dennis AL, van Baak MA, Blaak EE, Frayn KN, Saris WH, Karpe F: Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol 2006; 571: 451-460.
122. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN: Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002; 51: 2467-2473.
123. Jansson PA, Larsson A, Lonnroth PN: Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998; 28: 813-818.
124. Blaak EE, van Baak MA, Kemerink GJ, Pakbiers MT, Heidendal GA, Saris WH: Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995; 44: 183-187.
125. Samra JS, Simpson EJ, Clark ML, Forster CD, Humphreys SM, Macdonald IA, Frayn KN: Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism. Am J Physiol 1996; 271:E834-839.
126. Edens NK, Leibel RL, Hirsch J: Mechanism of free fatty acid re-esterification in human adipocytes in vitro. J Lipid Res 1990; 31: 1423-1431.
127. Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.
128. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I: Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911.
129. Ye J, Gao Z, Yin J, He Q: Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007; 293:E1118-1128.
130. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A: Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006; 341: 549-556.
131. Wang B, Wood IS, Trayhurn P: Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007; 455: 479-492.
132. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV: Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes 2008; 32: 451-463.
133. Kabon B, Nagele A, Reddy D, Eagon C, Fleshman JW, Sessler DI, Kurz A: Obesity decreases perioperative tissue oxygenation. Anesthesiology 2004; 100: 274-280.
134. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR: Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009; 58: 718-725.